JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banks, W. A.
Right arrow Articles by Arimura, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banks, W. A.
Right arrow Articles by Arimura, A.

Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood- brain barrier

WA Banks, AJ Kastin, G Komaki and A Arimura

Veterans Affairs Medical Center, New Orleans, Louisiana.

Pituitary adenylate cyclase activating polypeptide (PACAP) is a newly discovered regulatory peptide related to vasoactive intestinal peptide and is found widely distributed throughout peripheral tissues and the central nervous system. We examined the ability of its two major forms of 38 (P38) and 27 (P27) amino acid residues to cross the murine blood- brain barrier. After i.v. injection, [125I]P27 had a unidirectional influx constant (Ki) into the brain of 2.13 (10(-3)) ml/g/min with no saturable component to entry. Despite being larger and less lipophilic, [125I]P38 entered the brain more than 30% faster by a saturable transport system. A peptide-T analog related to PACAP that has its own saturable transport system did not inhibit the entry of [125I]P38, but did alter its binding to vascular receptors. Despite the greater Ki of [125I]P38, a larger percentage of the i.v. dose of [125I]P27 entered the brain due to favorable pharmacokinetics. However, [125I]P38 was more resistant to degradation within the brain and, after correction for degradation, its Ki increased to 16.5 (10(-3)) ml/g/min. The influences of peripheral degradation and sequestration by capillaries were negated by use of the brain perfusion and capillary depletion methods. These showed that the Ki into the brain interstitial fluid/parenchymal space for [125I]P38 was 15.3 (10(-3)) ml/g/min and was again inhibited with unlabeled P38. Both PACAPs were transported out of the central nervous system and inhibited the efflux of the other, but there was a [125I]P38 preferring subcomponent to the transport system.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 267, Issue 2, pp. 690-696, 11/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
BloodHome page
K. Freson, K. Peeters, R. De Vos, C. Wittevrongel, C. Thys, M. F. Hoylaerts, J. Vermylen, and C. Van Geet
PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications
Blood, February 15, 2008; 111(4): 1885 - 1893.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Ohtaki, T. Nakamachi, K. Dohi, Y. Aizawa, A. Takaki, K. Hodoyama, S. Yofu, H. Hashimoto, N. Shintani, A. Baba, et al.
Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6
PNAS, May 9, 2006; 103(19): 7488 - 7493.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
W. A. Banks, M. J. During, and M. L. Niehoff
Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration
J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 469 - 475.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. Nonaka, S. Shioda, M. L. Niehoff, and W. A. Banks
Characterization of Blood-Brain Barrier Permeability to PYY3-36 in the Mouse
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 948 - 953.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. K. Olszewski, M. M. Wirth, T. J. Shaw, M. K. Grace, and A. S. Levine
Peptides that Regulate Food Intake: Effect of peptide histidine isoleucine on consummatory behavior in rats
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2003; 284(6): R1445 - R1453.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
W. A. Banks, M. Goulet, J. R. Rusche, M. L. Niehoff, and R. Boismenu
Differential Transport of a Secretin Analog across the Blood-Brain and Blood-Cerebrospinal Fluid Barriers of the Mouse
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1062 - 1069.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
W. A. Banks, M. L. Niehoff, R. L. Brown, Z.-Y. Chen, and T. E. Cleveland
Transport of an Antifungal Trypsin Inhibitor Isolated from Corn across the Blood-Brain Barrier
Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2633 - 2635.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
K. Filipsson, M. Kvist-Reimer, and B. Ahren
The Neuropeptide Pituitary Adenylate Cyclase-Activating Polypeptide and Islet Function
Diabetes, September 1, 2001; 50(9): 1959 - 1969.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
W. A. Banks, S. A. Farr, W. Butt, V. B. Kumar, M. W. Franko, and J. E. Morley
Delivery across the Blood-Brain Barrier of Antisense Directed against Amyloid beta : Reversal of Learning and Memory Deficits in Mice Overexpressing Amyloid Precursor Protein
J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1113 - 1121.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1993 by the American Society for Pharmacology and Experimental Therapeutics.